Read Summary

Women with newly diagnosed ovarian cancer and a BRCA mutation see sustained benefits in progression free survival rates after two years of maintenance olaparib therapy, a clinical trial analysis suggests.
Reuters Health Information

Print Friendly, PDF & Email